US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 1.23 against a street estimate of 1.39 — a miss of 11.5%.
Analysts rate Prestige Brand Holdings Inc a buy (3 buy, 3 hold, 1 sell out of 7) with an average price target of $66.80.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.60% |
| Ariel Investments, LLC | 9.02% |
| Vanguard Portfolio Management, LLC | 5.92% |
| Dimensional Fund Advisors, Inc. | 5.64% |
| Kayne Anderson Rudnick Investment Management LLC | 4.65% |
| Vanguard Capital Management, LLC | 4.42% |
| State Street Corp | 4.16% |
| Allspring Global Investments Holdings, LLC | 3.29% |
| Document | Date |
|---|---|
| Material agreement · Q3 2026 | 2026-07-15 |
| Material agreement · Q2 2026 | 2026-07-06 |
| Proxy statement · Q2 2026 | 2026-06-29 |
| Material agreement · Q2 2026 | 2026-06-16 |
| Annual report FY2026 | 2026-05-14 |
| Results announced · Q2 2026 | 2026-05-13 |
| Quarterly report · Q4 2025 | 2026-02-05 |
| Quarterly report · Q3 2025 | 2025-11-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Prestige Brand Holdings Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.